immunic, inc (IMUX)

Immunic, Inc. (IMUX) a late-stage biotech company, released financial results for the second quarter ended June 30, 2026, reporting a wider loss than a year ago, driven by higher operating expenses. Company Profile Immunic is focused on developing oral therapies for neurologic diseases. The company's...

Immunic, Inc. (IMUX), a late-stage biotechnology company, on Wednesday said it has appointed Erik Lundgren as its new chief executive officer, effective May 22, 2026, with employment set to begin on June 1. Lundgren succeeds Daniel Vitt, who will continue to oversee scientific strategy and portfolio...

Immunic, Inc. (IMUX), Tuesday announced the appointment of Michael Panzara, as Chief Medical Officer, succeeding Andreas Muehler, effective April 24, 2026. In this new role, he will lead the company's development organization, including clinical development, medical affairs, and regulatory affairs,...

Immunic, Inc. (IMUX) has announced an oversubscribed private placement of up to $400 million, a financing designed to support the company's transition from a late-stage R&D organization into a fully integrated commercial-stage biotechnology company.

Immunic, Inc. (IMUX), a biotechnology company developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced Tuesday new, positive long-term open-label extension or OLE data from Phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) in relapsing-remitting...